19:52 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Cirius NASH candidate improves liver enzymes in Phase IIb

Cirius Therapeutics Inc. (Kalamazoo, Mich.) reported interim data from 328 evaluable patients with biopsy-proven non-alcoholic steatohepatitis (NASH) with fibrosis and no cirrhosis in the Phase IIb EMMINENCE trial showing that MSDC-0602K reduced liver enzymes from...
00:55 , Mar 16, 2018 |  BioCentury  |  Emerging Company Profile

Cirius safety

Cirius Therapeutics Inc. is developing a second-generation insulin sensitizer for non-alcoholic steatohepatitis that is designed to avoid cardiovascular symptoms and edema associated with first-generation agents. Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone from Takeda Pharmaceutical Co....
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Metabolic Solutions preclinical data

In a mouse model of PD, MSDC-0160 improved motor deficits, restored neurotransmitter levels in the striatum and protected dopaminergic neurons in the substantia nigra. Data were presented at the Grand Challenges in Parkinson's Disease meeting...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Clinical News

Mitoglitazone: Phase IIa data

A double-blind, U.S. Phase IIa trial in 29 non-diabetic patients aged 55-85 with mild AD showed that once-daily 150 mg MSDC-0160 met the primary endpoint of improving regional glucose metabolism levels in regions of the...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

Mitoglitazone: Phase IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 266 Type II diabetics showed that once-daily 100 and 150 mg MSDC-0160 each met the primary endpoint of reducing FPG from baseline to week 12...
01:34 , Jun 12, 2012 |  BC Extra  |  Clinical News

Metabolic Solutions' TZD analog meets Phase IIb diabetes endpoint

Metabolic Solutions Development Co. (Kalamazoo, Mich.) said once-daily 100 and 150 mg MSDC-0160 each met the primary endpoint of reducing fasting plasma glucose from baseline to week 12 vs. placebo in a Phase IIb trial...